Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 1.47
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of PYC.AX is 3.7 and suggests 144% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Data is available to registered users only
Buy
Sell